Global Testosterone Booster Market, by Component (Vitamins, D-Aspartic Acid, Zinc and Others), by Source (Mucuna Pruriens Ginseng, Oyster Extract, Fenugreek and Others), by Distribution Channel (Pharmacies, Hypermarkets & Supermarkets, Online Channels and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) is estimated to be valued at US$ 305.7 Mn in 2022 and is expected to exhibit a CAGR of 5.6% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key trends in market include increasing prevalence of chronic diseases being witnessed around the globe and resulting rise in demand for advanced therapeutics to cure reduced levels of testosterone which is expected to drive the growth of global testosterone booster market over the forecast period. For instance, according to an article published in National Center for Biotechnology Information, in February 2022, there were 437.9 million prevalent cases of type 2 diabetes in 2019, with an age-standardized point prevalence of 5282.9 per 100,000 populations, which represents a 49% increase since 1990, globally.
Global Testosterone Booster Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, Contract research organization (CROs), and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. An April 2020 study for The Impact of COVID-19 on Clinical Trial Sites conducted by Medidata, a life sciences software provider that supports clinical trials with a primary focus on evidence generation, suggests that investigative sites demonstrated flexibility and ingenuity in adopting new approaches in order to cope with challenges presented by the pandemic, with over half of investigative sites transitioning to virtual approaches to interact with patients. More recently, follow-up studies performed in August 2020 have identified persistent impact of COVID-19 pandemic, with over 60% reporting an average or greater level of impact on ongoing trials and initiation of new trials. Respondents specifically highlighted challenges in patient enrollment and recruitment. Recently, the U.S. FDA guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or put new processes in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.